Real-World study eyes drug combo for tough prostate cancer
NCT ID NCT07674121
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatment and how long before they need another therapy. The goal is to gather real-world data from the GCC region to inform future treatment guidelines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib and abiraterone combination
What this could lead to
If successful, this study could provide real-world evidence to support using this drug combination earlier in treatment for men with metastatic prostate cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It is also small (75 participants) and limited to the GCC region, which may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••